5.4 Additional Refinements

Refinements to the SGR process that have been discussed above can be considered simultaneously. Tables 15a and 15b document effects on CFs of sequentially imposing two refinements on the rebased model with drug and lab spending excluded from SGR spending: use of the higher SGR values (displayed in Table 12), e.g., to accommodate desire for higher target spending; and elimination of the cumulated spending portion of the UAF, e.g., to reduce effects of past behavior on the update.

An increase in the SGR in addition to elimination of drug and lab spending would increase CFs because higher spending targets reduce levels of over-spending and make it easier for providers to achieve update increases. With larger SGRs, the CF in 2010 would be $38.03 (Table 15a) versus $34.69 (Table 14a). When the cumulated spending portion of the UAF is then eliminated, rates at which CFs fall would be reduced because the penalty of over-spending is lessened (Table 15b), which would increase CFs even more through 2010.

Table 15a. Rebasing V. Modification of SGR Spending with Revised SGRs:CFs, 2007-2014
	*Rebased*			Less Lab and Drug Spending, With Revised SGRs
Update Year (t)	SGR	CFt	Percent Change	SGR	CFt	Percent Change
2007	1.007	38.88	2.60	1.018	38.88	2.60
2008	1.039	37.19	-4.36	1.053	38.22	-1.70
2009	1.035	35.35	-4.95	1.048	38.05	-0.45
2010	1.029	33.55	-5.08	1.042	38.03	-0.05
2011	1.034	32.51	-3.10	1.047	38.90	2.30
2012	1.042	32.23	-0.87	1.056	40.54	4.20
2013	1.045	32.39	0.50	1.059	42.47	4.77
2014	1.039	32.74	1.08	1.053	44.53	4.83
Notes: Rebased estimates on left side are as in Table 13a; baseline data in italics subject to change. Estimates on right side were derived by (1) rebasing after deleting drug and lab spending from SGR spending, and (2) using SGR values that were revised to reflect CMS's revision experience and increased by 1 percentage point (values displayed in Table 12). Rebased means that in calculating the CF for 2007, the target for 2006 is estimated spending for 2006, and initial cumulated actual and target spending amounts are set to total estimated 2006 spending; the SGR formula was then applied for years 2007-2014.

At the same time, relative rates of increase in CFs would be reduced because cumulated under-spending does not occur when the cumulated spending portion of the UAF is eliminated. The latter would occur during 2011-2014 (Table 15b versus 15a).

Each refinement would increase program spending. Spending with rebased targets would be $774.9 billion between 2007 and 2013 (v. $711.9 billion under baseline). During this period, elimination of drug and lab spending from total SGR spending would increase program spending by $25.1 billion ($800.0-$774.9 billion, Table 14b). Increases in the SGR would increase spending by an additional $63.5 billion ($863.5-$800.0 billion, Table 16a). Elimination of the cumulated spending portion of the UAF would increase spending by another $6.4 billion ($869.9-$863.5 billion, Table 16b).

Table 15b. Rebasing V. Modification of SGR Spending with Revised SGRs and UAF: CFs, 2007-2014
	*Rebased*					Less Lab and Drug Spending, With Revised SGRs and UAFs
Update Year (t)	SGR	Cumulated Spending Weight	CFt	Percent Change	SGR	Cumulated Spending Weight	CFt	Percent Change
2007	1.007	0.33	38.88	2.60	1.018	0.00	38.88	2.60
2008	1.039	0.33	37.19	-4.36	1.053	0.00	38.67	-0.56
2009	1.035	0.33	35.35	-4.95	1.048	0.00	38.75	0.21
2010	1.029	0.33	33.55	-5.08	1.042	0.00	38.82	0.18
2011	1.034	0.33	32.51	-3.10	1.047	0.00	39.49	1.72
2012	1.042	0.33	32.23	-0.87	1.056	0.00	40.71	3.09
2013	1.045	0.33	32.39	0.50	1.059	0.00	42.24	3.76
2014	1.039	0.33	32.74	1.08	1.053	0.00	43.96	4.07
Notes: Rebased estimates on left side are as in Table 13a; baseline data in italics subject to change. Estimates on right side were derived by (1) rebasing after deleting drug and lab spending from SGR spending, (2) using SGR values that were revised to reflect CMS's revision experience and increased by 1 percentage point (values displayed in Table 12), and (3) eliminating the cumulated spending term from the UAF. Rebased means that in calculating the CF for 2007, the target for 2006 is estimated spending for 2006, and initial cumulated actual and target spending amounts are set to total estimated 2006 spending; the SGR formula was then applied for years 2007-2014.

Table 16a. Rebasing V. Modification of SGR Spending with Revised SGRs: Spending, 2007-2013
Period	Physician	Lab and Drug	Total	Physician	Lab and Drug	Total	Spending Ratio
	*Rebased (billions)*			Less Lab and Drug Spending, With Revised SGRs
2007-2010	347.4	82.2	429.6	368.0	82.2	450.2	1.05
2011-2013	265.0	80.3	345.4	333.0	80.3	413.3	1.20
Total	612.4	162.5	$774.9	701.0	162.5	$863.5	1.11
Notes: See notes, Table 15a. Spending estimates were derived using CFs displayed in Table 15a. The Spending Ratio is the ratio of spending with revisions (right side) to baseline rebased spending (left side).

Table 16b. Rebasing V. Modification of SGR Spending with Revised SGRs and UAF: Spending, 2007-2013
	*Rebased (billions)*			Less Lab and Drug Spending, With Revised SGRs and UAFs
Period	Physician	Lab and Drug	Total	Physician	Lab and Drug	Total	Spending Ratio
2007-2010	347.4	82.2	429.6	372.8	82.2	455.0	1.06
2011-2013	265.0	80.3	345.4	334.3	80.3	414.7	1.20
Total	612.4	162.5	$774.9	707.2	162.5	$869.7	1.12
Notes: See notes, Table 15b. Spending estimates were derived using CFs displayed in Table 15b. The Spending Ratio is the ratio of spending with revisions (right side) to baseline rebased spending (left side).

View full report

Download

"sgr.pdf" (pdf, 309.97Kb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®

Tags:

Was this page helpful? *

Yes

No

Leave this field blank

Form Approved OMB# 0990-0379 Exp. Date 9/30/2020

Short-Term Fixes to the Sustainable Growth Rate Process . 5.4 Additional Refinements

Similar content

View full report